• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Episode 22 - Antiplatelet Agents Explored

Video

Because of recently updated recommendations by the American College of Cardiology Foundation and American Heart Association about how to treat patients with cardiovascular disorders with antiplatelet therapy, Michael Weber, MD, discusses his personal recommendations.

Kenneth L. Schaecher, MD, FACP, CPC, briefly explains both the clinical and economic outcomes demonstrated through treatment with these agents, and because a large number of antiplatelet drugs are developing, David Calabrese, RPh, MHP, discusses how newer agents address treatment gaps and have better economic value when compared to older agents.

Although Dr Schaecher agrees with the potential of these new drugs, he concludes that there are still many unanswered questions about the ability of these agents to treat patients at risk for developing cardiometabolic events.


Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Robert Zimmerman, MD
Leslie Fish, PharmD.
Ronesh Sinha, MD
Beau Raymond, MD
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.